Skip to main content
Premium Trial:

Request an Annual Quote

David Martin, Frank McCormick, Peter Stadler, Pierre Hochuli, Shane Grey, Monica Tamborini


David Martin will serve as the chairman of the steering committee of PharmaStart, a drug discovery collaboration announced last week that will be led by SRI International and includes Stanford University; University of California, San Diego; University of California, San Francisco; and the UCSF campus of the California Institute for Quantitative Biomedical Research. Martin is a former professor of medicine and biochemistry at UCSF; former executive vice president at Genentech, and later DuPont Merck; president of Chiron Therapeutics, and most recently a founder and CEO of Eos Biotechnology, a partner of Affymetrix.


Frank McCormick has joined the board of directors of South San Francisco-based Exelixis. McCormick is director of the University of California, San Francisco, Comprehensive Cancer Center, and the David A. Wood Professor of Tumor Biology and Cancer Research in the department of microbiology and immunology at UCSF. Previously, he was founder and CSO of Onyx Pharmaceuticals; vice president of research at Chiron; and vice president of research at Cetus. He completed postdoctoral fellowships at the Imperial Cancer Research Fund of London, and at the State University of New York at Stony Brook. McCormick holds a PhD in biochemistry from the University of Cambridge, and a BS in biochemistry from the University of Birmingham (UK). Peter Stadler, managing director of Artemis Pharmaceuticals of Germany, resigned from the board, the company said in a statement.


Pierre Hochuli was named the chairman of the board of Devgen of Ghent, Belgium, replacing Piet Strijkert, the company said last week. Hochuli previously was executive vice president of Mon-santo and a managing partner of PolyTechnos, a Munich-German based venture capital firm, where he served as an observer on the Devgen board. Devgen conducts drug discovery operations based on a C. elegans model.


Shane Grey has been named to the scientific advisory board of CombiMatrix, the company announced last week. Grey is an assistant professor of surgery at Harvard Medical School. Grey holds a 1995 PhD in immunology and pathology from Monash University in Australia. He conducted post-doctoral studies at the Sandoz Center for Immunobiology in Boston and will become a member of the Garvan Institute of Medical Research in Sydney, Australia, this year.


Monica Tamborini joins DNAPrint Genomics as chief financial and operations officer, the Sarasota, Fla.-based company said last week. Previously, Tamborini was CFO for Calix of Petaluma, Calif., and subsidiary Pharm-eco Laboratories.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.